Amoy Diagnostics
Amoy Diagnostics, Amgen Partner on Lung Cancer CDx Development for Lumakras in Japan
Amoy Diagnostics will develop its PCR-based panel as a companion diagnostic in Japan to screen NSCLC patients for Amgen's KRAS G12C inhibitor.
Amoy Diagnostics CDx Gets Japanese Approval to ID NSCLC Patients Eligible for Tepmetko
The Japanese Ministry of Health, Labor, and Welfare has approved AmoyDx's PLC Panel for use in identifying NSCLC patients with MET exon 14 skipping alterations.
AmoyDx PCR Panel Receives Japanese Approval as CDx for Non-Small Cell Lung Cancer Therapies
The Japanese MHLW approved the real-time PCR-based test as a CDx to detect four driver genes for nine associated NSCLC targeted therapies.
AmoyDx, AstraZeneca Strike Ovarian Cancer Companion Diagnostic Alliance
The companies have worked together on a number of other cancer-related projects, including a companion diagnostic for the ovarian cancer treatment olaparib.
Amoy Diagnostics, Merck KGaA Partner for Lung Cancer Companion Diagnostic Development in China
AmoyDx will develop and seek regulatory approval in China for a lung cancer PCR panel to be used with Merck's MET inhibitor tepotinib.
Jan 3, 2020
Nov 25, 2019
AmoyDx, Eisai Form CDx Development Alliance
Oct 12, 2018
AmoyDx Lung Cancer CDx Approved in South Korea
Jan 29, 2018
AmoyDx, Medikonia Ink MDx Distribution Deal
May 16, 2017
Amoy Dx Partners With Canbridge on CDx Development
Oct 17, 2014